Barco Uniforms Launches COVID-19 Scrub Donation Program

Barco Uniforms pledges to donate 10,000 scrubs each month for the duration of the coronavirus pandemic to healthcare professionals on the front line treating patients who have been infected. Donations will be prioritized and distributed based on requests made by Healthcare teams who submit a scrub donation request on Barco’s website.

“We are launching our scrub donation program to show our sincere thanks and demonstrate our immense gratitude to Healthcare professionals all over the country, all of whom have been so heroic in the fight against this pandemic,” said Barco Uniforms president/CEO David Murphy. “We are here to support the Healthcare workers as they take care of all of us.”

Scrub donations include all seven of Barco’s brand collections, including Barco OneTM, Grey’s AnatomyTM and SkechersTM by Barco.

“We are launching our scrub donation program to show our sincere thanks and demonstrate our immense gratitude to Healthcare professionals all over the country, all of whom have been so heroic in the fight against this pandemic,” said Barco Uniforms president/CEO David Murphy. “We are here to support the Healthcare workers as they take care of all of us.”

Barco Uniforms has served Healthcare professionals for over 90 years and has been built on the belief that those in the Healthcare and services industries are multidimensional individuals with their own experiences of risk, vulnerability and struggle. The company’s Made to Matter philosophy, was created to give back and honor the spirit of healthcare professionals around the world. “Serving those who serve others has been a pillar of our legacy for over 90 years and at the forefront of everything we do, but these words have never had greater strength and deeper meaning than they do today during these unprecedented times,” added Murphy.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”